Jennifer Takata, DO
Internal Medicine · Salem, WINPI 1992724249
Payments from drug & device makers
Across 77 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aimmune Therapeutics, Inc.$321
- AstraZeneca$209
- Pfizer$149
- Novo Nordisk$148
- Boehringer Ingelheim$141
- Nestle Healthcare Nutrition Inc.$125
- plus $451 from 15 others
What the payments were for
- Food & beverage$1,544100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aimmune Therapeutics, Inc. | 13 | $321 |
| AstraZeneca | 12 | $209 |
| Pfizer | 8 | $149 |
| Novo Nordisk | 7 | $148 |
| Boehringer Ingelheim | 8 | $141 |
| Nestle Healthcare Nutrition Inc. | 5 | $125 |
| Daiichi Sankyo Inc. | 5 | $88 |
| Exact Sciences | 3 | $70 |
| AbbVie | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Lundbeck LLC | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Vertex | 1 | $22 |
| Amgen | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| GSK | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
How this compares
$1,544 in reported general payments places this provider in the 90th percentile of 1,411 internal medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 155 | $249,330 |
| EliquisApixaban | 119 | $121,130 |
| OzempicSemaglutide | 58 | $95,141 |
| XareltoRivaroxaban | 45 | $54,292 |
| JanuviaSitagliptin Phosphate | 39 | $47,816 |
| FarxigaDapagliflozin Propanediol | 47 | $41,558 |
| JardianceEmpagliflozin | 31 | $39,987 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $18,624 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 137 | $17,859 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $10,350 |
| Gabapentin | 265 | $9,090 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $7,995 |
| Omeprazole | 424 | $7,577 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $7,362 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $7,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $15 | $249,330155 claims |
| PfizerEliquis, Prempro | $149 | $124,215132 claims |
| Novo NordiskOzempic | $148 | $95,14158 claims |
| Johnson & JohnsonXarelto | $15 | $54,29245 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $141 | $47,34943 claims |
| AstraZenecaFarxiga, Symbicort | $209 | $46,76970 claims |
| GSKBreo Ellipta, Anoro Ellipta | $17 | $26,61946 claims |
| AbbVieSynthroid | $59 | $4,31781 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,411 internal medicine providers in Wisconsin.
Other internal medicine in Salem
- Nicholas SiebersMadison$47.3M
- Irene MirkinMiddleton$42.9M
- John BlanchardMadison$17.2M
- Carlos SanabriaWest Bend$12.9M
- Andrew KimWauwatosa$2.3M
- Jeremiah DeptaMilwaukee$2.2M
- Gilbert JenouriMilwaukee$2.2M
- Stephen FlachMadison$1.6M
- Aliaksandr TrusauGreen Bay$1.5M
- Samuel IdarragaWauwatosa$743K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.